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The recent advent of next-generation
sequencing (NGS) has revolutionized the
way we study human diseases in general,
and cancer in particular. Novel method-
ologies and platforms made it possible
to resequence, at single nucleotide resolu-
tion, entire human exomes, genomes, and
epigenomes in a matter of weeks at pro-
gressively lower costs. Combined with the
possibility of small lab-based setups, this
potential leveraged the implementation of
such technologies within individual labo-
ratories. This has been of particular impor-
tance when numerous genetic tests are
required for the evaluation of a given con-
dition, when the condition is genetically
heterogeneous, or when genetic testing is
not available to confirm a suspected diag-
nosis (1). In the context of this third
scenario, genetic diagnosis has evolved
into the implementation of multi-gene
sequencing panels, which proved particu-
larly effective for several hereditary condi-
tions (one disease/multiple genes) leading
to improvements on the informed genetic
testing, prevention, early detection, and
management of individuals at high cancer
risk (2).
The rationale for the design of multi-
gene panels invariably relies on the avail-
able knowledge at a certain time. For
cancer-associated syndromes, it is com-
mon to select the main causative gene(s)
known; to add gene(s) causing other syn-
dromes in which the cancer of interest
recurrently appears (as part of the tumor
spectrum); to identify genes harboring
somatic mutations in the cancer of inter-
est, and; eventually, to select genes that
cause cancer in other tissues with common
embryologic origin. The interpretation of
the role of germline mutant genes, when
a rationale is present for their selection,
is definitely easier than the interpretation
of whole exome/genome data, which con-
sistently generates data that surpasses our
capacity to draw clinical utility out of it.
The whole exome/genome data hold other
difficulties, which are commonly referred
to as incidental or secondary findings.
These “unwanted” and frequently “unex-
plainable” discoveries depend on the avail-
able knowledge, increase the complexity of
counseling and management, and are of
little use to doctors and patients (3, 4).
A new challenge emerged when
germline biallelic mutations in MUTYH
were found to greatly increase lifetime risk
of colorectal cancer and familial aggrega-
tion, raising the awareness for inherited
autosomal recessive cancer syndromes (5).
Although rare, recessive cancer syndromes
may explain the occurrence of cancer
aggregation in a proportion of families.
The globalization of NGS infrastruc-
tures and the application of this technol-
ogy, to so far mutation negative families,
will also increase the possibility of trans-
forming monogenic diseases into multi-
genic diseases. It is possible that in some
kindred, for which no high penetrance sus-
ceptibility gene has been identified, that
the combination of germline heterozygotes
in lower susceptibility loci, is responsible
for the establishment of the phenotype.
This possibility would explain lower disease
penetrance in some families, variable dis-
ease spectrum, and eventually late or early
disease onset, if one of the genes acts as a
modifier (positive/negative). If factual, this
will be soon uncovered with genome-wide
approaches.
Overall, NGS will provide, in the near
future, a large array of germline mutant
genes, which may or may not explain the
source of genetic syndromes. The challenge
for researchers and clinicians will be to
choose the right variant(s) and to prove its
role as causative in each individual case.
More than ever, combined, and multidis-
ciplinary efforts are required to help deci-
phering genotype–phenotype correlations
in inherited diseases, and to translate NGS
data into clinical utility.
There are a few other issues that are
worth revisiting when defining cancer-
associated syndromes, namely related with
the need to disclose histological sub-types
of pre-malignant or neoplastic lesions, age
of disease onset, and intra-familial disease
spectrum.
In several cancer-associated syndromes,
histological subtype classification is
mandatory to allocate families into syn-
dromes and define the genetic test to be
recommended. When pathology reports
are missing, clinical criteria may not apply,
and the likelihood of families being coun-
seled toward genetic testing decreases.
Demonstrating this are morphologically
heterogeneous diseases like gastric cancer,
for which at least two syndromes have been
described (FIGC – familial intestinal gas-
tric cancer and HDGC – hereditary diffuse
gastric cancer), which are mainly differen-
tiated based on tumor histo-pathological
features (6). As inherited genetic defects
have only been found for HDGC (7, 8), all
families presenting with aggregation of gas-
tric cancer that do not comply with clinical
www.frontiersin.org March 2015 | Volume 5 | Article 62 | 1
Pinheiro et al. NGS challenges in hereditary cancer
criteria of HDGC, will not undergo genetic
testing. This dependence on pathological
data for adequate genetic testing, although
useful when single genes were offered
in diagnosis, currently limits or prevents
the finding of potential causative genetic
events, if NGS is applied. So, perhaps
genetic testing should not be barred after a
given specific pathology diagnosis has been
advanced, as it remains unknown whether
the established anatomy-based tumor clas-
sification is reflected on the genetic level.
The finding of a given gene involved in
several apparently different cancer-related
syndromes, in distinct histological cancer
sub-types, or even in distinct organ cancer
types will represent a new dimension on
the old problem of genotype–phenotype
association. This situation is exemplified
in a study addressing renal cell carcinoma
(RCC) in the context of Cowden syndrome
(CS) (9). In this work, the same PTEN
germline nonsense mutation was identified
in three probands that presented with three
different tumor histologies (9). Although
the reasons for this remain unknown,
it is possible that in CS-RCC, PTEN
haplo-insufficiency could cooperate with
secondary events (germline or somatic),
which may act as genetic modifiers and
contribute to promote transformation
along distinct histological pathways (9).
We can therefore anticipate that the
histological information from a given
tumor may even be “disregarded” concern-
ing directing a patient, and their family
toward genetic testing (a specific gene/gene
panels/full exome). However, histological
information should not be overlooked
when a genetic defect has been identified,
and it is necessary to define a patient’s prog-
nosis and to design adequate surveillance,
and treatment strategies.
Early age of disease onset has been
recurrently used to define clinical crite-
ria for cancer-associated syndromes, which
often restricts testing to those diagnosed
with a given cancer under a certain age.
However, families presenting with aggre-
gation of cancer, although at later ages of
onset than that indicated in clinical criteria,
may still present with a germline defect that
causes familial aggregation of a given dis-
ease. This issue has been elegantly explored
in a cohort of Lynch syndrome patients and
has opened the way for the relaxation of
clinical criteria (10).
Intra-familial disease spectrum is
another interesting issue to re-examine
in the NGS era, as mutations in cancer
genes commonly associated with specific
familial disorders, start emerging as the
inherited cause in completely different
syndromes. This is the case of CDH1
germline mutations, accepted to cause
HDGC, and discovered as the cause of
familial breast cancer in families lack-
ing BRCA gene mutations (11). Another
example is the presence of TP53 muta-
tions in families with high incidences of
gastric cancer, and lacking the classical Li-
Fraumeni associated tumor types (12, 13).
Actually, TP53 germline mutations may be
involved in many more cases than initially
anticipated, as demonstrated by the high
frequency of TP53 germline mutations
found in a cohort of unselected cancer
patients (14).
All these findings and observations seem
to favor the relaxation of clinical crite-
ria for selecting individuals at greater risk
of developing familial cancer. In fact, and
according to growing evidence, families
with aggregation of cancer, independently
of age of onset or organ tropism, should
be guided for genetic testing, the same way
that individuals with very early age of onset,
but lacking family history of cancer. Favor-
ing this approach is the fact that a specific
syndrome and a specific gene, no longer
need to be pinpointed for screening if a
multi-gene panel is available. On the other
hand, such a strategy may be debatable as
the costs of screening may increase, despite
the general decrease in price of NGS prod-
ucts and services, due to the large number
of patients/families that become eligible
for testing with the broadening of clinical
criteria.
In summary, the way we have been look-
ing at hereditary cancer risk is changing,
and it is urgent to revisit clinical criteria,
screening strategies, and clinical manage-
ment of families with aggregation of cancer
in light of the new and still confounding
next-gen data, which becomes available on
a daily basis.
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